Quick Answer
Pasithea Therapeutics Corp. reported Diluted EPS of $2.91 per share (loss) for fiscal year 2025.
Pasithea Therapeutics Corp. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.91 | +77.1% |
| 2024 | -$12.69 | -2294.3% |
| 2022 | -$0.53 | -152.4% |
| 2021 | -$0.21 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.41 | +85.7% | +37.9% |
| June 30, 2025 | -$0.66 | +82.2% | +59.0% |
| March 31, 2025 | -$1.61 | +56.5% | +43.9% |
| September 30, 2024 | -$2.87 | — | +22.6% |
| June 30, 2024 | -$3.71 | -37000.0% | -0.3% |
| March 31, 2024 | -$3.70 | -36900.0% | — |
| September 30, 2023 | $0.00 | +100.0% | +100.0% |
| June 30, 2023 | -$0.01 | +50.0% | +0.0% |
- Pasithea Therapeutics Corp. showed an increase of +77.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, Pasithea Therapeutics Corp.’s diluted eps has declined by 1285.7% (from $0.21 per share (loss) to $2.91 per share (loss)).
- The most recent figure is from Pasithea Therapeutics Corp.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: